RGRyan Gately

Ryan Gately

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Ryan Gately has a total of 89 co-authors. Here are the top co-authors by number of shared publications:

  • Carmel Hawley

    Department of Kidney and Transplant Services, Princess Alexandra Hospital, Brisbane, QLD, Australia; Australasian Kidney Trials Network, University of Queensland, Brisbane, QLD, Australia; Translational Research Institute, The University of Queensland, Brisbane, QLD, Australia

    5 shared publications
  • Germaine Wong

    Sydney School of Public Health, University of Sydney, Sydney, NSW, Australia; Centre for Kidney Research, Kids Research Institute, The Children's Hospital at Westmead, Sydney, NSW, Australia; Department of Renal Medicine, Westmead Hospital, Sydney, NSW, Australia

    5 shared publications
  • Germaine Wong

    School of Public Health, University of Sydney, Sydney, New South Wales, Australia

    5 shared publications
  • Armando Teixeira-Pinto

    Centre for Kidney Research, Kids Research Institute, The Children’s Hospital at Westmead, Sydney, Australia

    4 shared publications
  • Armando Teixeira-Pinto

    Sydney School of Public Health, University of Sydney, Sydney, NSW, Australia; Centre for Kidney Research, Kids Research Institute, The Children's Hospital at Westmead, Sydney, NSW, Australia

    3 shared publications
  • Scott B. Campbell

    Department of Kidney and Transplant Services, Princess Alexandra Hospital, Brisbane, QLD, Australia

    3 shared publications

Latest Publications

  • Open Access

    Transplantation and Mortality as Competing Outcomes Among Patients on Dialysis With Newly Diagnosed Cancer: A Longitudinal Cohort Study

    by Ryan Gately, Eric A. Engels, Dharshana Sabanayagam, Armando Teixeira-Pinto, Scott Campbell, Carmel Hawley, Wai Lim, Germaine Wong

  • Open Access

    Advances in survival analyses: machine learning methods and model comparison

    by Ryan Gately, Dharshana Sabanayagam, Wai H. Lim, Lin Zhu, Farzaneh Boroumand, Shuvo Bakar, Armando Teixeira-Pinto, Germaine Wong


  • Techniques to predict survival outcomes in nephrology: basics and traditional methods

    by Ryan Gately, Germaine Wong, Armando Teixeira-Pinto

  • Open Access

    BEAT-BK: An Adaptive, Randomized Controlled Trial to Treat Polyomavirus Infections (BKPyV) in Kidney and Kidney-pancreas Transplantation Recipients (BEAT-BK) Study Protocol

    by Ryan Gately, Michael Dymock, Dharshana Sabanayagam, Scott B. Campbell, Jonathan C. Craig, Vikas Dharnidharka, Anna Francis, Jonathan M. Gleadle, Martin Hajek, Sana Hamilton, et al.

    Background.: BK polyomavirus (BKPyV) is a common opportunistic infection in kidney transplant recipients, typically reactivating in the context of immunosuppression. Although asymptomatic in immunocompetent individuals, reactivation in transplant recipients can cause BKPyV-associated nephropathy (BKPyVAN), a leading cause of graft dysfunction and loss. BKPyV viremia affects approximately 10%–15% of transplant recipients, and once BKPyVAN is established, the risk of graft failure can exceed 50%. The current standard of care involves immunosuppression reduction to restore virus-specific immunity, but this approach increases the risk of acute and chronic rejection. Intravenous immunoglobulin (IVIg), which contains antiviral and immunomodulatory antibodies, has been proposed as an adjunctive therapy, although evidence supporting its efficacy remains limited to small observational studies. Methods.: The BEAT-BK trial is a multicenter, adaptive, randomized controlled trial comparing standard immunosuppression reduction with or without IVIg in kidney and simultaneous pancreas-kidney transplant recipients with BKPyV viremia or biopsy-confirmed BKPyVAN. The trial will enroll participants aged 2 y and older, randomizing them 1:1 to receive standard care alone or in combination with a total IVIg dose of 2 g/kg for 8 wk. An adaptive Bayesian design will permit interim analyses with the potential for early trial success or futility. Results.: The primary endpoint is a composite ordinal outcome at 12 wk, incorporating death, graft loss, estimated glomerular filtration rate decline, acute rejection, viral load, and degree of immunosuppression reduction. Secondary outcomes include viral clearance, development of BKPyVAN and donor-specific antibodies, infections, malignancy, quality of life, and cost-effectiveness. Conclusions.: This trial will provide the first high-quality evidence on the role of IVIg in BKPyV management and inform clinical decision-making in posttransplant care.

  • Open Access

    Association Between Donor-recipient Matchability, Access to Transplantation, and Posttransplant Outcomes

    by Rowena Lalji, Ryan Gately, Ross Francis, Wai Lim, Scott Campbell, Narelle Watson, Gary Torrens, Anna Francis, Germaine Wong, David W. Johnson

    Background.: Globally, deceased donor kidney allocation algorithms prioritize HLA matching, potentially disadvantaging transplant candidates with less common HLA alleles. This study developed an Australian Matchability score (M-score) to assess access to transplantation and posttransplant outcomes based on HLA match probability. Methods.: M-scores were calculated by comparing all recipients and donors with complete HLA-A, HLA-B, and HLA-DR data from the Australia and New Zealand Dialysis and Transplant Registry (July 1, 2006–December 31, 2023). Multivariable Cox regression was used to analyze associations between M-score quartiles and time to transplantation as well as transplantation outcomes. Results.: HLA data from 14 836 recipients and 7708 donors were used to generate M-scores. Of these, 10 760 recipients had available waitlist data and were included in the models. M-scores were normally distributed with a mean ± SD of 11.4 ± 0.9. The proportion of non-European Australians increased significantly with each quartile (ie, more difficult to HLA match), Q1: 16%, Q2: 26%, Q3: 40% Q4: 60% (P < 0.001). Compared with Q1, patients in Q4 were significantly less likely to receive a deceased donor kidney transplant (adjusted hazard ratio [aHR] 0.56; 95% confidence interval [CI], 0.52-0.60; P < 0.001) had the highest risk of death-censored graft loss (aHR 1.39; 95% CI, 1.01-1.91; P = 0.05) and acute rejection (aHR, 1.29; 95% CI, 1.09-1.52; P = 0.002). Conclusions.: The M-score identifies transplant recipients with difficult-to-match HLA profiles. Higher M-scores were associated with a lower likelihood of transplantation and an increased risk of death-censored graft loss and acute rejection. These findings highlight significant inequities in the current HLA-based algorithm for deceased donor allocation.


  • Open Access

    Dual‐Energy X‐Ray Absorptiometry‐Derived Advanced Hip Analysis and the Trabecular Bone Score Are Associated With the Diagnosis of Fracture Following Kidney and Simultaneous Pancreas‐Kidney Transplantation

    by Tahira Scott, Jasna Aleksova, Carmel Hawley, Mina Khair, Harpreet Kaur, Christopher Schultz, Ryan Gately, Mirna Vucak‐Dzumhur, James Elhindi, Grahame J. Elder

    Background: Patients with kidney failure have elevated fracture risk that remains high following kidney transplantation. This study aimed to assess whether dual‐energy x‐ray absorptiometry‐derived advanced hip analysis (AHA) and the trabecular bone score (TBS) improve bone mineral density (BMD)‐based post‐transplant fracture prediction.Methods: Patients receiving kidney‐only or simultaneous pancreas‐kidney (SPK) transplants underwent immediate post‐transplant dual‐energy x‐ray absorptiometry to provide BMD, the TBS, and AHA parameters; femoral neck, calcar, and shaft cortical thickness (CTh), and femoral neck buckling ratio (BR), an index of structural instability. Patients received treatment to reduce post‐transplant BMD loss, using an established risk algorithm. Hazard ratios were determined using Kaplan–Meier and Cox proportional hazard models.Results: Of 357 transplant recipients, 289 (83%) received a kidney‐only transplant. There were 83 incident fractures over a median of 4.4 years (IQR: 2.5–5.5). Fracture was associated with type 1 diabetes mellitus (p < 0.001), former smoking (p = 0.006), lower 25‐hydroxyvitamin D (p = 0.003), BMD at total proximal femur and neck of femur (p < 0.001) and spine (p = 0.008), lower CTh at the calcar (p = 0.005) and shaft (p = 0.023), higher BR (p = 0.016) and lower TBS (p = 0.047). Following multivariable adjustment, type 1 diabetes mellitus, 25‐hydroxyvitamin D, smoking, and femoral neck BMD remained significant. Using the BMD‐based risk algorithm, inclusion of the BR improved the model fit.Conclusion: BMD, the TBS, and AHA parameters are associated with incident fracture in kidney‐only and SPK transplant recipients. Pre‐transplant smoking, lower 25‐hydroxyvitamin D and BMD are potentially modifiable factors that could reduce post‐transplant fracture risk.


  • Open Access

    Comparison Between Antigen and Allelic HLA Mismatches, and the Risk of Acute Rejection in Kidney Transplant Recipients

    by Ryan Gately, Anne Taverniti, Narelle Watson, Armando Teixeira‐Pinto, Esther Ooi, Rowena Lalji, Ross Francis, Lucy Sullivan, William Mulley, Kate Wyburn, et al.

    Deceased donor kidney allocation relies on HLA compatibility at the antigen level, as optimal matching reduces the risk of acute rejection. Whether HLA allele‐level mismatches improve, the prediction of acute rejection after transplantation remains unclear. Using data from the Australia and New Zealand Dialysis and Transplant Registry (ANZDATA) from 2017 to 2020, HLA antigenic and allelic mismatches between recipients and deceased donors were calculated with imputation of two‐field allelic equivalents undertaken where required. The discordance between antigen and allele mismatches was calculated, and oblique random survival forest models were used to predict acute rejection. Predictive performance of antigen (HLA‐A, ‐B, ‐DRB1 and ‐DQB1), allele (HLA‐A, ‐B, ‐DRB1 and ‐DQB1) and extended allele (HLA‐A, ‐B, ‐C, ‐DRB1, ‐DQA1 and ‐DQB1) models was examined using concordance index and integrated Brier scores, with variable importance calculated using permutation‐based methods. Among 2644 recipients followed for a median of 1.7 years, 521 recipients (20%) experienced acute rejection. Discordant numbers of antigenic and allelic mismatches occurred in 8%, 9%, 24% and 17% of HLA‐A, ‐B, ‐DRB1 and ‐DQB1 loci, respectively. Predictive performances were similar across all models, with concordance indices of 0.62–0.63 and integrated Brier scores of 0.09. HLA‐DRB1 and ‐DQB1 mismatches were the strongest predictors of acute rejection across models. In patients matched at the HLA‐DRB1 or ‐DQB1 antigen, those with allelic mismatches had similar incidences of rejection compared to those without. Allelic‐level assessment of HLA compatibility did not improve the prediction of acute rejection and may disadvantage certain recipients by reclassifying them into higher mismatch categories in allocation algorithms without providing clear clinical benefit.


  • Open Access

    Access to Waitlisting and Posttransplant Outcomes in Patients With Failed Kidney Allografts Secondary to Recurrent Glomerulonephritis

    by Ryan MMedStat Gately, Germaine Wong, Armando Teixeira-Pinto, Helen Pilmore, Carmel MMedStat Hawley, Scott Campbell, William Mulley, Wai H. Lim

    Background.: Recurrent glomerulonephritis (GN) is an important cause of allograft loss after transplantation when GN is the primary cause of kidney failure. Retransplantation after allograft loss from recurrent disease requires careful consideration. We aimed to determine the probability of relisting and the risk of allograft loss after retransplantation in recipients with prior allograft loss from recurrent GN. Methods.: Using data from the Australia and New Zealand Dialysis and Transplant Registry and multivariable Cox modeling, we compared the probability of waitlisting and allograft loss after second transplantation between those with and without prior allograft loss from recurrent disease. Results.: Of 3276 patients who received a second kidney transplant, 179 (5%) lost their first allograft from recurrent GN. Between 2006 and 2021, 1524 patients with failed first allografts (6% with recurrent GN, 45% with primary GN but no disease recurrence) were relisted for transplantation. Compared with patients without primary GN, the adjusted hazard ratios (95% confidence intervals) for relisting in patients with primary GN, with and without disease recurrence, were 1.09 (0.88-1.34) and 1.16 (1.05-1.29), respectively. The respective adjusted hazard ratios for allograft loss after repeat transplantation were 0.77 (0.59-1) and 1.02 (0.9-1.16). Of the 81 patients who received a second allograft after losing their first allograft to GN recurrence, 18 patients (22%) also lost their second allograft because of recurrent GN. Conclusions.: Patients with prior allograft loss from GN recurrence were not disadvantaged, with comparable waitlist potential and allograft outcome after repeat transplantation. However, >20% of those with prior allograft loss from disease recurrence also lost their second allografts from recurrent disease.

  • Using causal directed acyclic graphs (DAGs) to select patient-important outcomes in transplantation trials—interventions to treat polyomavirus infection as an example

    by Yue Wu, Michael Dymock, Ryan Gately, Julie A. Marsh, Carmel Hawley, Germaine Wong, Thomas L. Snelling


  • Open Access

    Incidence, Risk Factors, and Outcomes of Kidney Transplant Recipients With BK Polyomavirus-Associated Nephropathy

    by Ryan Gately, Elasma Milanzi, Wai Lim, Armando Teixeira-Pinto, Phil Clayton, Nicole Isbel, David W. Johnson, Carmel Hawley, Scott Campbell, Germaine Wong